Antimicrobial stewardship in children: more shadows than lights?

Expert Rev Anti Infect Ther. 2019 Nov;17(11):871-876. doi: 10.1080/14787210.2019.1686355. Epub 2019 Nov 1.

Abstract

Introduction: The aim of this review is to evaluate the effectiveness of antimicrobial stewardship (AMS) programmes in the pediatric population in improving clinical outcomes, altering prescribing behavior, controlling antimicrobial resistance and measuring the cost-effectiveness.Areas covered: Medline Ovid MEDLINE(R), Embase, and Cochrane Library were searched on 30 September 2018 combining MeSH and free terms for 'antimicrobial stewardship', 'clinical outcomes', 'antimicrobial resistance', 'cost-effectiveness' and 'prescribing behavior'. Several studies have been conducted on the impact of antimicrobial stewardship programmes (ASPs) in children, which showed a positive impact on length of hospital stay and days of therapy. Together with ASP bundles, the introduction of fast microbiology and point-of-care tests showed a positive impact in terms of rapid identification of the pathogen, time to optimal antimicrobial therapy and reduction of antibiotic use, without worsening clinical outcomes. These improvements turned out to be limited over time. Conflicting results were observed regarding the impact of ASPs on antimicrobial resistance and on cost-effectiveness and cost-benefits, due to the lack of homogeneity between studies.Expert opinion: Evidence regarding the impact of ASPs in children is limited to single center studies, with different study designs, making it impossible to draw unequivocal conclusions. High quality studies are needed. More feasable approaches should be designed both for inpatients and outpatients and for critical patients.

Keywords: Antibiotic stewardship; antimicrobial resistance; children; clinical outcomes; cost-effectiveness.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / administration & dosage*
  • Antimicrobial Stewardship / economics
  • Antimicrobial Stewardship / organization & administration*
  • Child
  • Cost-Benefit Analysis
  • Drug Resistance, Microbial
  • Humans
  • Practice Patterns, Physicians' / standards*
  • Research Design

Substances

  • Anti-Infective Agents